Some joint symptoms need care sooner than others

Heat, fever, or sudden weakness needs prompt care

Fever with a swollen, hot joint could come from an infection. After an injury, get fast care if you suddenly can't put weight on the leg. Loss of feeling or strength is serious, especially with bladder or bowel trouble.

Severe swelling after a treatment also needs quick attention. Don't wait for a clinic appointment if symptoms feel dangerous. Urgent care or an emergency department can assess the problem.

Your medicines and health can change the choice

An infection or bleeding problem may make a procedure unsafe. Blood-thinning medicine, such as aspirin, slows the way blood seals a cut and needs careful review before a shot. Don't stop it unless the clinician who prescribed it agrees.

Current cancer care is another reason for medical review first. Take a full list of your medicines to the clinic. The clinician can then explain why a treatment may need to wait.

Severe joint wear may call for another opinion

Pain at rest, a changed joint shape, or very limited motion can point to severe wear. A surgical opinion can explain whether an operation now makes more sense. You can hear that view without agreeing to surgery.

The clinician can say when clinic care isn't a sound fit. QC Kinetix offers consultations that review your history, exam, and non-surgical choices. That honest limit is part of a useful visit.

Sources

1. The OARSI non-surgical management guideline evaluated 60 interventions with GRADE methodology and built its recommendations around core treatments - structured exercise, weight management and self-management education - for every patient with knee osteoarthritis, regardless of what else is added.

   Bannuru RR, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

2. A systematic review of 21 studies re-examining the familiar '20 percent are dissatisfied after knee replacement' figure found the actual average dissatisfaction rate was 10 percent, and 7.3 percent when complications were excluded - the surgical benchmark a cash-pay injection is implicitly competing against.

   DeFrance MJ, et al. — Are 20% of Patients Actually Dissatisfied Following Total Knee Arthroplasty? A Systematic Review of the Literature. J Arthroplasty, 2023. DOI: 10.1016/j.arth.2022.10.011.

3. A 2019 survey identified 40 US companies operating 76 clinics marketing 'cell therapy' for eye conditions, most using autologous adipose-derived cells, concentrated in California, Florida and Illinois - a map of how far the marketplace reaches beyond orthopedics.

   Nirwan RS, et al. — Assessing "Cell Therapy" Clinics Offering Treatments of Ocular Conditions using Direct-to-Consumer Marketing Websites in the United States. Ophthalmology, 2019. DOI: 10.1016/j.ophtha.2019.03.019.

4. A comprehensive review of published case reports, clinical reports and media accounts catalogued the safety incidents associated with unproven stem cell interventions and the factors driving the global growth of the 'stem cell tourism' market.

   Bauer G, et al. — Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions. Stem Cells Transl Med, 2018. DOI: 10.1002/sctm.17-0282.

5. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.